Ligand Pharmaceuticals Inc. Insider Trading

LGND

Last 12 months

Insiders sold $36.9M and bought nothing on the open market.

69% of the selling was scheduled in advance under 10b5-1 plans. Director Jason Haas sold $2.09M on Aug 12, 64% of their stake, outside a plan. The last open-market buy by an executive or director was in May 2025.

Net open-market

−$36.9M

0 buys · 31 sales

Under a 10b5-1 plan

69%

of the value sold

Insiders who bought / sold

0 / 9

executives and directors

Last open-market buy

May 2025

May 9, 2025

Get an email when LGND's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 2	Andrew Reardon CLO & Secretary	Sold10b5-1 plan 13 parts	5,000	$313.22 average	$1.57M	14%	Form 4
Oct 30 – Nov 2	Jason Aryeh Director	SoldNo plan 6 parts	2,111	$320.30 average	676K	1.8%	Form 4
Oct 2	Andrew Reardon CLO & Secretary	Sold10b5-1 plan 6 parts	5,000	$304.07 average	$1.52M	14%	Form 4
Sep 10	Martine Zimmermann Director	SoldNo plan	1,200	$285.00	342K	24%	Form 4
Sep 3	Andrew Reardon CLO & Secretary	Sold10b5-1 plan 5 parts	5,000	$286.09 average	$1.43M	12%	Form 4
Aug 12	Octavio Espinoza Chief Financial Officer	Sold10b5-1 plan	31,641	$292.07	$9.24M	53%	Form 4
Aug 12	Jason Haas Director	SoldNo plan	7,138	$292.81	$2.09M	64%	Form 4
Aug 3	Andrew Reardon CLO & Secretary	Sold10b5-1 plan 10 parts	5,000	$288.99 average	$1.44M	11%	Form 4
Jul 1	Andrew Reardon CLO & Secretary	Sold10b5-1 plan 8 parts	5,000	$313.28 average	$1.57M	11%	Form 4
Jun 16	Stephen L Sabba Director	SoldNo plan	2,145	$254.00	545K	6.0%	Form 4
Jun 12	Jason Haas Director	SoldNo plan 2 parts	6,461	$255.58 average	$1.65M	56%	Form 4
Jun 10 – 11	Jason Aryeh Director	SoldNo plan 2 parts	5,000	$250.00 average	$1.25M	4.1%	Form 4
Jun 10	John L Lamattina Director	SoldNo plan 4 parts	4,591	$250.88 average	$1.15M	15%	Form 4
Jun 1	Andrew Reardon CLO & Secretary	Sold10b5-1 plan 7 parts	5,000	$227.06 average	$1.14M	11%	Form 4
May 1 – 13	John W Kozarich Director	Sold10b5-1 plan 7 parts	2,501	$225.14 average	563K	5.6%	Form 4
May 1	Andrew Reardon CLO & Secretary	Sold10b5-1 plan 7 parts	5,000	$231.31 average	$1.16M	11%	Form 4
Apr 1	John W Kozarich Director	Sold10b5-1 plan 5 parts	467	$202.22 average	94K	1.1%	Form 4
Apr 1	Andrew Reardon CLO & Secretary	Sold10b5-1 plan 6 parts	5,000	$201.24 average	$1.01M	11%	Form 4
Mar 23	Stephen L Sabba Director	SoldNo plan	1,000	$207.87	208K	3.0%	Form 4
Mar 11	Octavio Espinoza Chief Financial Officer	Sold10b5-1 plan	3,057	$225.00	688K	13%	Form 4
Mar 6	John L Lamattina Director	SoldNo plan	2,161	$200.76	434K	6.6%	Form 4
Mar 4	Andrew Reardon CLO & Secretary	Sold10b5-1 plan 11 parts	5,000	$206.35 average	$1.03M	12%	Form 4
Mar 4	Octavio Espinoza Chief Financial Officer	Sold10b5-1 plan 11 parts	13,423	$205.83 average	$2.76M	38%	Form 4
Mar 3	Stephen L Sabba Director	SoldNo plan	2,034	$201.50	410K	5.7%	Form 4
Mar 2	John W Kozarich Director	Sold10b5-1 plan 6 parts	467	$200.50 average	94K	1.1%	Form 4
Feb 2	John W Kozarich Director	Sold10b5-1 plan 5 parts	467	$195.91 average	91K	1.1%	Form 4
Jan 2	John W Kozarich Director	Sold10b5-1 plan 5 parts	467	$189.58 average	89K	1.1%	Form 4
Dec 12, 2025	Octavio Espinoza Chief Financial Officer	SoldNo plan	1,804	$188.31	340K	6.4%	Form 4
Dec 1, 2025	John W Kozarich Director	Sold10b5-1 plan 7 parts	467	$195.84 average	91K	1.0%	Form 4
Nov 7, 2025	Nancy Ryan Gray Director	SoldNo plan 2 parts	6,571	$205.45 average	$1.35M	45%	Form 4
Nov 7, 2025	John L Lamattina Director	SoldNo plan 2 parts	4,179	$205.45 average	859K	12%	Form 4
Nov 3, 2025	John W Kozarich Director	Sold10b5-1 plan 4 parts	467	$191.05 average	89K	1.0%	Form 4
Oct 1, 2025	John W Kozarich Director	Sold10b5-1 plan 4 parts	467	$179.45 average	84K	1.0%	Form 4
Sep 23, 2025	Jason Aryeh Director	SoldNo plan 3 parts	10,000	$170.81 average	$1.71M	7.4%	Form 4
Sep 2, 2025	John W Kozarich Director	Sold10b5-1 plan 3 parts	467	$162.26 average	76K	1.0%	Form 4
Aug 1, 2025	John W Kozarich Director	Sold10b5-1 plan	467	$131.88	62K	1.0%	Form 4
Jul 10, 2025	John W Kozarich Director	Sold10b5-1 plan	934	$125.00	117K	2.0%	Form 4
Jun 23, 2025	Andrew Reardon CLO & Secretary	SoldNo plan	500	$114.08	57K	1.5%	Form 4
Jun 10, 2025	Andrew Reardon CLO & Secretary	SoldNo plan	500	$114.54	57K	1.5%	Form 4
May 15, 2025	Andrew Reardon CLO & Secretary	SoldNo plan	1,000	$104.00	104K	2.9%	Form 4

Nov 210b5-1 plan
Andrew Reardon
CLO & Secretary · sold 5,000 at avg $313.22
$1.57M
14% of stake
Oct 30 – Nov 2No plan
Jason Aryeh
Director · sold 2,111 at avg $320.30
676K
1.8% of stake
Oct 210b5-1 plan
Andrew Reardon
CLO & Secretary · sold 5,000 at avg $304.07
$1.52M
14% of stake
Sep 10No plan
Martine Zimmermann
Director · sold 1,200 at $285.00
342K
24% of stake
Sep 310b5-1 plan
Andrew Reardon
CLO & Secretary · sold 5,000 at avg $286.09
$1.43M
12% of stake
Aug 1210b5-1 plan
Octavio Espinoza
Chief Financial Officer · sold 31,641 at $292.07
$9.24M
53% of stake
Aug 12No plan
Jason Haas
Director · sold 7,138 at $292.81
$2.09M
64% of stake
Aug 310b5-1 plan
Andrew Reardon
CLO & Secretary · sold 5,000 at avg $288.99
$1.44M
11% of stake
Jul 110b5-1 plan
Andrew Reardon
CLO & Secretary · sold 5,000 at avg $313.28
$1.57M
11% of stake
Jun 16No plan
Stephen L Sabba
Director · sold 2,145 at $254.00
545K
6.0% of stake
Jun 12No plan
Jason Haas
Director · sold 6,461 at avg $255.58
$1.65M
56% of stake
Jun 10 – 11No plan
Jason Aryeh
Director · sold 5,000 at avg $250.00
$1.25M
4.1% of stake
Jun 10No plan
John L Lamattina
Director · sold 4,591 at avg $250.88
$1.15M
15% of stake
Jun 110b5-1 plan
Andrew Reardon
CLO & Secretary · sold 5,000 at avg $227.06
$1.14M
11% of stake
May 1 – 1310b5-1 plan
John W Kozarich
Director · sold 2,501 at avg $225.14
563K
5.6% of stake
May 110b5-1 plan
Andrew Reardon
CLO & Secretary · sold 5,000 at avg $231.31
$1.16M
11% of stake
Apr 110b5-1 plan
John W Kozarich
Director · sold 467 at avg $202.22
94K
1.1% of stake
Apr 110b5-1 plan
Andrew Reardon
CLO & Secretary · sold 5,000 at avg $201.24
$1.01M
11% of stake
Mar 23No plan
Stephen L Sabba
Director · sold 1,000 at $207.87
208K
3.0% of stake
Mar 1110b5-1 plan
Octavio Espinoza
Chief Financial Officer · sold 3,057 at $225.00
688K
13% of stake
Mar 6No plan
John L Lamattina
Director · sold 2,161 at $200.76
434K
6.6% of stake
Mar 410b5-1 plan
Andrew Reardon
CLO & Secretary · sold 5,000 at avg $206.35
$1.03M
12% of stake
Mar 410b5-1 plan
Octavio Espinoza
Chief Financial Officer · sold 13,423 at avg $205.83
$2.76M
38% of stake
Mar 3No plan
Stephen L Sabba
Director · sold 2,034 at $201.50
410K
5.7% of stake
Mar 210b5-1 plan
John W Kozarich
Director · sold 467 at avg $200.50
94K
1.1% of stake
Feb 210b5-1 plan
John W Kozarich
Director · sold 467 at avg $195.91
91K
1.1% of stake
Jan 210b5-1 plan
John W Kozarich
Director · sold 467 at avg $189.58
89K
1.1% of stake
Dec 12, 2025No plan
Octavio Espinoza
Chief Financial Officer · sold 1,804 at $188.31
340K
6.4% of stake
Dec 1, 202510b5-1 plan
John W Kozarich
Director · sold 467 at avg $195.84
91K
1.0% of stake
Nov 7, 2025No plan
Nancy Ryan Gray
Director · sold 6,571 at avg $205.45
$1.35M
45% of stake
Nov 7, 2025No plan
John L Lamattina
Director · sold 4,179 at avg $205.45
859K
12% of stake
Nov 3, 202510b5-1 plan
John W Kozarich
Director · sold 467 at avg $191.05
89K
1.0% of stake
Oct 1, 202510b5-1 plan
John W Kozarich
Director · sold 467 at avg $179.45
84K
1.0% of stake
Sep 23, 2025No plan
Jason Aryeh
Director · sold 10,000 at avg $170.81
$1.71M
7.4% of stake
Sep 2, 202510b5-1 plan
John W Kozarich
Director · sold 467 at avg $162.26
76K
1.0% of stake
Aug 1, 202510b5-1 plan
John W Kozarich
Director · sold 467 at $131.88
62K
1.0% of stake
Jul 10, 202510b5-1 plan
John W Kozarich
Director · sold 934 at $125.00
117K
2.0% of stake
Jun 23, 2025No plan
Andrew Reardon
CLO & Secretary · sold 500 at $114.08
57K
1.5% of stake
Jun 10, 2025No plan
Andrew Reardon
CLO & Secretary · sold 500 at $114.54
57K
1.5% of stake
May 15, 2025No plan
Andrew Reardon
CLO & Secretary · sold 1,000 at $104.00
104K
2.9% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch LGND, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with LGND

CompareIntrinsic value

SNDXSyndax Pharmaceuticals Inc.

$10.45-26.87%0

SDGRSchrodinger, Inc.

$28.52+4.93%36

RYTMRhythm Pharmaceuticals Inc.

$110.68+28.04%40

PHATPhathom Pharmaceuticals Inc.

$5.68-1.05%10

HROWHarrow Inc.

$28.75+0.74%46

PBYIPuma Biotechnology Inc.

$10.69+4.60%68

RIGLRigel Pharmaceuticals, Inc.

$51.29+4.97%87

VNDAVanda Pharmaceuticals Inc.

$3.88+3.47%10

Held by ETFs

LGND is in 107 US ETFs. The largest of them, with LGND's weight in each:

Spot a number that looks wrong? Check it in LGND's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing LGND

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.